Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aligos Therapeutics, Inc. - Common stock (NQ: ALGS )

39.84 +1.49 (+3.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 469,153
Open 36.78
Bid (Size) 39.00 (2)
Ask (Size) 40.41 (5)
Prev. Close 38.35
Today's Range 36.35 - 41.64
52wk Range 6.760 - 41.64
Shares Outstanding 42,940,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in December
From Aligos Therapeutics
Via GlobeNewswire

Performance

YTD
+124.64%
+124.64%
1 Month
+101.31%
+101.31%
3 Month
+391.85%
+391.85%
6 Month
+271.47%
+271.47%
1 Year
+127.66%
+127.66%

More News

Read More
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in October
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Reverse Stock Split
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Strengthens Board with Two New Independent Directors
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
From Aligos Therapeutics
Via GlobeNewswire
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Via Talk Markets
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
From Aligos Therapeutics
Via GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
From Aligos Therapeutics
Via GlobeNewswire
ALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.